 |
|
|
| |
Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic
Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Harry L.A. Janssen,1 Pietro Lampertico,2 Chi-Yi Chen,3 Jeong Heo,4 Claire Fournier,5 Sang Hoon Ahn,6 Tak Yin Owen Tsang,7 Carla Coffin,8 Giulio Marchesini Reggiani,9 Yi-Hsiang Huang,10 Aric Josun Hui,11 Magdy Elkhashab,12
Chien-Hung Chen,13 Syed Mohammed Raza Jafri,14 Susanna K. Tan,15 Shuyuan Mo,15 Vithika Suri,15 John F. Flaherty,15 Anuj Gaggar,15 Mani Subramanian,15 Kosh Agarwal,16 Wan-Long Chuang,17 Edward Gane,18 Young-Suk Lim19
1Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 2Centro di Riferimento per la Diagnosi e lo Studio delle Malattie del Fegato e delle Vie Biliari "Angela Maria ed Antonio Migliavacca," Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy; 3Chia-Yi Christian Hospital, Chiayi City, Taiwan; 4Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea;
5Centre Hospitalier de l'Université de Montréal, Québec, Canada; 6Yonsei Liver Center, Severance Hospital, Seoul, South Korea; 7Princess Margaret Hospital, Hong Kong; 8Calgary Liver Unit, University of Calgary, Alberta, Canada; 9Università di Bologna, Italy; 10Taipei Veterans General Hospital, Taipei City, Taiwan; 11Alice Ho Miu Ling Nethersole Hospital, Hong Kong; 12Toronto Liver Centre, Toronto; 13Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, and Chang Gung University College of Medicine, Taoyuan City, Taiwan; 14Henry Ford Hospital, Detroit, Michigan, USA; 15Gilead Sciences, Inc., Foster City, California, USA; 16Institute of Liver Sciences, King's College London, UK; 17Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City; 18Auckland Clinical Studies, Auckland, New Zealand; 19Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
References: 1. Agarwal K, et al. J Hepatol 2015;62:533-40; 2. Babusis D, et al. Mol Pharm 2013;10:459-66; 3. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 4. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 5. Lampertico P, et al. The Digital International Liver Congress 2020, oral SAT091; 6. Lampertico P, et al. Lancet Gastroenterol Hepatol. 2020;5:441-53; 7. Janssen H, et al. AASLD 2019, poster 483.
Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
